ProKidney (MEX:PROK) Short-Term Capital Lease Obligation : MXN18.12 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ProKidney Short-Term Capital Lease Obligation?

ProKidney's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was MXN18.12 Mil.

ProKidney's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 (MXN11.78 Mil) to Dec. 2023 (MXN13.63 Mil) and increased from Dec. 2023 (MXN13.63 Mil) to Mar. 2024 (MXN18.12 Mil).

ProKidney's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (MXN5.48 Mil) to Dec. 2022 (MXN9.61 Mil) and increased from Dec. 2022 (MXN9.61 Mil) to Dec. 2023 (MXN13.63 Mil).

ProKidney Short-Term Capital Lease Obligation Historical Data

The historical data trend for ProKidney's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Short-Term Capital Lease Obligation Chart

ProKidney Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

4.48

5.48

9.61

13.63

ProKidney Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial									11.25	11.21	11.78	13.63	18.12

ProKidney Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

ProKidney Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of ProKidney's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

ProKidney (MEX:PROK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (MEX:PROK) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

PROK:USA

Address

2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103

Website

https://www.prokidney.com

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.